Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdeVac-Flu
- Development stage
- Unknown
- Lead developer
- NantPharma
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
AdeVac-Flu is a recombinant pseudoadenoviral vector vaccine developed by NantPharma (also known as NTpharma) for the prevention of human influenza. The vaccine utilizes a pseudoadenoviral nanoparticle platform to deliver hemagglutinin (HA) genes from specific influenza strains, typically including A/H1N1, A/H3N2, and Influenza B, as recommended by the WHO. Upon intranasal administration, the pseudoadenoviral particles deliver the genetic material into human cells, which then express the hemagglutinin protein to elicit a protective immune response. This modality is designed to provide seasonal protection against circulating influenza viruses through a non-invasive delivery route.
- Brand names
- AdeVac-Flu
- Other names
- recombinant pseudoadenoviral influenza vaccineNTpharma influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on AdeVac-Flu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdeVac-Flu.